FiercePharmaOriginal article
{"a":[{"_":"In a first, Otsuka’s Voyxact stabilizes IgAN patients’ kidney function decline to normal levels","$":{"href":"/pharma/first-otsuka-voyxact-stabilizes-igan-patients-kidney-function-decline-normal-levels","hreflang":"en"}}]}
Phase 3positiveVoyxactPositive
AI Analysis
Summary
Otsuka's Voyxact demonstrated in a Phase 3 trial that it can stabilize kidney function decline in IgA nephropathy patients to normal levels, a first-ever achievement for the indication.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Stabilized kidney function decline to normal levels in IgAN patients
Importance:7/10
Sentiment:
0.85
IgA nephropathykidney functionPhase 3positive data
Related Companies
Read the original article
Published by FiercePharma on August 3, 2026 3:44 PM